Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand

BACKGROUND: Public payer reimbursement for non-oncology drugs in Canada, including orphan drugs, is based on recommendations by the Common Drug Review (CDR) (with the exception of Quebec). CDR has been criticized for negative recommendations for orphan drugs and contributing to delays in patient acc...

Descripción completa

Detalles Bibliográficos
Autores principales: McCormick, John I., Berescu, L. Diana, Tadros, Nabil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791218/
https://www.ncbi.nlm.nih.gov/pubmed/29382371
http://dx.doi.org/10.1186/s13023-018-0759-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791218/
https://www.ncbi.nlm.nih.gov/pubmed/29382371
http://dx.doi.org/10.1186/s13023-018-0759-9

Ejemplares similares